Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

Summary

Type 2 diabetes is common, increases in prevalence with age, and patients with diabetes have an increased risk of cardiovascular disease. A relatively new cardiovascular medication currently used for the treatment of heart failure in the United States inhibits an enzyme that breaks down a variety of signaling hormones. This clinical trial tests if it may also be a target for the treatment of diabetes by decreasing the breakdown of a hormone that increases insulin release after a meal.

Timeline

Start

2018-06-01

Primary completion

2026-06-01

Completion

2026-06-30

Drugs

Indications